Gilead Shells Out $510M For YM BioSciences
HIV drug giant Gilead Sciences Inc. will purchase fellow biotechnology company YM BioSciences Inc. for $510 million in cash to gain development rights for a promising bone-marrow disorder treatment, the companies...To view the full article, register now.
Already a subscriber? Click here to view full article